Study of Oxygen Therapy in Improving Stem Cell TransplantResearch Question:
Will the use of hyperbaric oxygen (HBO) therapy prior to the UCB transplant improve
the stem cell homing, and subsequently, the engraftment?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
Umbilical Cord Blood (UCB) as a graft source for a bone marrow transplant has drawbacks
related to the limited cell dose available for transplant and defects in homing. Homing
is the process of UCB stem cell lodging in the bone marrow. If the homing is not efficient
it could delay the re-population of the stem cells (or engraftment), possibly lead
to engraftment failure, and delay the rebuilding of the immune system after transplant.
This could, in turn, provide a higher risk to infection after the UCB transplant.
This research study is aimed at investigating the use of hyperbaric oxygen (HBO) therapy
prior to the UCB transplant to find out if it will improve the stem cell homing, and
subsequently, the engraftment. HBO therapy involves breathing 100% pure oxygen while
in a sealed chamber that has been pressurized at 2 ½ times the normal atmospheric
There is a specific hormone which tells stem cells in the bone marrow to make more
red blood cells. This hormone (called EPO) is increased when blood oxygen levels are
low. When the EPO is increased, it might impair the bone marrow homing process of
your transplant. Therefore, the researchers conducting this study hope to determine
if providing 100% pure oxygen to you prior to your UCB transplant will decrease this
hormone, and in turn, improve the homing process after your transplant.
Study Reference #: UBMT17044
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Kaitlyn Burrows
Phone: (585) 275-5150
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search